McAdam LLC Reduces Position in Pfizer Inc. $PFE

McAdam LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 37.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,968 shares of the biopharmaceutical company’s stock after selling 7,667 shares during the period. McAdam LLC’s holdings in Pfizer were worth $329,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PFE. Brighton Jones LLC boosted its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. Triumph Capital Management lifted its holdings in Pfizer by 20.0% during the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 1,717 shares in the last quarter. Gotham Asset Management LLC lifted its holdings in Pfizer by 333.4% during the 4th quarter. Gotham Asset Management LLC now owns 141,040 shares of the biopharmaceutical company’s stock valued at $3,742,000 after buying an additional 108,494 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Pfizer by 80.7% during the 4th quarter. Janus Henderson Group PLC now owns 958,315 shares of the biopharmaceutical company’s stock valued at $25,434,000 after buying an additional 427,886 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.5%

NYSE:PFE opened at $24.59 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $139.79 billion, a P/E ratio of 13.08, a P/E/G ratio of 0.88 and a beta of 0.55. The firm has a 50-day simple moving average of $24.83 and a 200-day simple moving average of $24.33. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer’s payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.